Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology.
Antoine BertolottiEmilie SbidianO Join-LambertI Bourgault-VilladaM Moyal-BarraccoP PerrotN JouanY YordanovS SidorkiewiczK ChazelasM-F Bru-DaprésE CaumesJ-F Seinull nullOlivier ChosidowMarie Beylot-Barrynull nullPublished in: The British journal of dermatology (2021)
Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease which impacts quality of life substantially. Its prevalence is estimated to 0.7%.1 Various pathophysiological hypotheses exist, but no therapeutic consensus, making the management of HS patients complex.